Standard BioTools Inc. (LAB:NASDAQ) closed at $0.606 on October 23, 2026, down 4.72% on the day. The stock trades 64.8% below its 52-week high of $1.72 and 1.9% above its 52-week low of $0.594. Over the past year, it lost 57.4%. Standard BioTools Inc. is part of the Capital Goods sector.
In 252 trading sessions since October 23, 2025, LAB closed higher on 100 days (40%). Its best day was January 8, 2026 (+20.31%) and its worst was June 8, 2026 (-30.43%). The stock moved 10% or more in a single session 7 times. It opened at least 5% above the previous day's high 1 time.
Fluidigm Corp manufactures life science tools focused on the analysis of single cells and industrial applications of genomics. These tools are based on microfluidics and mass cytometry technologies. It sells instruments and consumables, including integrated fluidic circuits, assays, and reagents. Slightly more than half of the firm's revenue comes from the sale of Consumables. Fluidigm primarily sells its products to academic institutions, clinical laboratories, and biopharmaceutical companies. The majority of revenue is generated in the United States followed by EMEA and Asia-Pacific.
Find more stocks like LAB with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.